On March 29, 2022, Sanofi and IGM Biosciences, Inc. announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only two target binding sites. Under the terms of the agreement, IGM will receive a $150 million upfront payment and potentially over $6 billion in aggregate development, regulatory, and commercial milestones. A 50:50 profit share in certain major market countries and tiered royalties in the rest of world is planned for oncology targets, and IGM will receive tiered royalties for autoimmune/inflammation targets. Wilson Sonsini Goodrich & Rosati advised IGM on the transaction.

The Wilson Sonsini team included:

Ken Clark
Miranda Biven
Norman Hovijitra
David Pirko
Sarah Siedlak
Myra Sutanto Shen
Joshua Gruenspecht
Anne Seymour
Todd Hahn
John Ceccio
Audrey Greene
Alexander Poonai​​​

For more information, please see IGM's press release.